




Article Contents

Abstract

[Skip to Main Content](#)

POSTER SESSION ABSTRACTS | MAY 02 2024

Abstract PO1-15-03: Spatially resolved analysis of tumor microenvironment in invasive lobular carcinoma **FREE**

Matteo Serra; Mattia Rediti; Laetitia Collet; Frédéric Lifrange; David Venet; Nicola Occelli; Xiaoxiao Wang; Delphine Vincent; Ghizlane Rouas; Ligia Craciun; Denis Larsimont; Laurence Buisseret; Miikka Vikkula; François Duhoux; Françoise Rothé; Christos Sotiriou



+ [Author & Article Information](#)

Cancer Res (2024) 84 (9_Supplement): PO1-15-03.

<https://doi.org/10.1158/1538-7445.SABCS23-PO1-15-03>

Split-Screen	Share ▾	Tools ▾	Versions ▾
--------------	---------	---------	------------

Abstract

Background: Invasive lobular carcinoma (ILC) is the second most common histological breast cancer subtype; however, little is known about its tumor microenvironment (TME). Here, we aimed to study ILC TME using spatial transcriptomics (ST). **Methods:** We performed ST (Visium 10x Genomics) on frozen tumor samples from 43 primary hormone receptor positive (HR+), HER2-negative (HER2-) ILCs. Of note, 9 samples were coming from patients who experienced disease relapse. Relative hematoxylin/eosin (H&E) slides were morphologically annotated (QuPath software). xCell was used to perform cell type enrichment analysis on sample pseudo-bulks. After cross-samples integration, ST spots were clustered using hierarchical clustering (STutility R package). intNMF algorithm was used to perform clustering at the patient-level by combining: RNA sequencing information (relative percentage of spot-level clusters in each sample), morphology and level of colocalization between cancer cells and the other cell types of the tumor microenvironment. METABRIC (HR+, HER2- ILC samples, n = 122) was used as external validation cohort. Survival analyses (univariable and multivariable adjusting for clinicopathological features) were performed using Cox proportional hazard models. **Results:** The patient-level classification revealed four groups

showing different biological characteristics. Differences in terms of morphology (annotation) and pathway enrichment analysis based on marker genes (GSEA) were observed between groups. This information allowed us to annotate our groups as: proliferative (P, n = 12, enriched in tumor cells and proliferation-related pathways), normal-stroma enriched (NSE, n = 10, enriched in fibroblasts and carcinoma in situ), metabolic (M, n = 9, enriched in metabolic-related pathways) and metabolic-immune enriched (MIE, n = 10, enriched in adipose tissue, metabolic and immune-related pathways). Interestingly, a significantly higher presence of macrophages M2 was found in MIE group. Using group-specific gene signatures, we were able to reproduce the same 4 groups in the METABRIC. Of note, we observed significant differences in relapse-free survival (RFS) in METABRIC ($p = 0.03$), with NSE presenting better outcome, while P, M and MIE presented worse prognosis. Analysing the area of contact between adipocytes and cancer cells typical of MIE group, we noticed an enrichment in metabolic and M2 macrophages-related pathways. In doing so, we derived a 28 gene signature relative to the tumor-adipocytes contact area. Importantly, our signature was highly expressed in M and MIE groups, and it was not correlated with proliferation-related signatures. Interestingly, the adipocytes-related signature was significantly associated with shorter RFS in ILC patients in METABRIC (univariable: HR 1.4, $p = 0.023$; multivariable: HR 1.6, $p = 0.005$). Since both proliferation and metabolism showed to be key processes in defining prognosis in ILC, we built a prognostic index by integrating our adipocytes-related signature with genomic grade index (GGI, a proliferation-related signature). Our index outperformed other existing prognostic signatures (e.g., Oncotype DX, MammaPrint, EndoPredict, LobSig) in assessing prognosis (RFS) in ILC in METABRIC (univariable: HR 1.7, $p < 0.001$; multivariable: HR 1.7, $p = 0.002$). Conclusions: We identified 4 biologically driven HR+, HER2- ILC groups describing tumor microenvironment heterogeneity. Of note, two of the three groups associated to worse disease outcome were related to metabolism, highlighting the importance of such process in ILC biology and in the future development of new treatment strategies. Moreover, the prognostic power of our index has the potential to refine the assessment of the risk of relapse in ILC. Further validation is warranted.


Citation Format: Matteo Serra, Mattia Rediti, Laetitia Collet, Frédéric Lifrange, David Venet, Nicola Occelli, Xiaoxiao Wang, Delphine Vincent, Ghizlane Rouas, Ligia Craciun, Denis Larsimont, Laurence Buisseret, Miikka Vikkula, François Duhoux, Françoise Rothé, Christos Sotiriou. Spatially resolved analysis of tumor microenvironment in invasive lobular carcinoma [abstract]. In: Proceedings of the 2023 San Antonio Breast

[Skip to Main Content](#)

Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-15-03.

©2024 American Association for Cancer Research

Advertisement



View Metrics

[Skip to Main Content](#)

Citing Articles Via

Google Scholar

Email Alerts

Article Activity Alert

eTOC Alert

Breaking

Trump's Call for Funding Freeze Retracted

Judge Temporarily Halts Federal Funding Freeze

T-DXd Approved for Another Indication

[View more recent articles >](#)

Latest News

Aspirin Halves Recurrence Risk of Some Colorectal Cancers

Shedding Light on Cancer's Lung-Metastatic Propensity

Genome Editing Sheds Light on BRCA2 Mutations

[View more recent articles >](#)

[Skip to Main Content](#)

Research Watch

BrainChild-03 Trial Supports Safety of B7-H3 CAR T-cell Therapy for DIPG

Tertiary Lymphoid Structures Are Activated by IL-33 in Pancreatic Cancer

The Initiation of Glioblastoma Induces a Brain Injury–Like Niche

[View more recent articles >](#)

Issues

News

Online First

Twitter

Collections

Online ISSN 1538-7445 **Print ISSN** 0008-5472

AACR Journals
[Skip to Main Content](#)

Blood Cancer Discovery
Cancer Discovery

Cancer Epidemiology,
Biomarkers &
Prevention

Information on Advertising &
Reprints



[Cancer Immunology
Research](#)

[Cancer Prevention
Research](#)

[Cancer Research](#)

[Cancer Research
Communications](#)

[Clinical Cancer
Research](#)

[Molecular Cancer
Research](#)

[Molecular Cancer
Therapeutics](#)

[Information for
Institutions/Librarians](#)

[RSS Feeds](#)

[Privacy Policy](#)

Copyright © 2025 by the American Association for Cancer Research.